Clinical and karyotype characteristics of patients with inv(16)(p13q22) AML
| Patient . | Sex/age, y . | Therapy . | Type of transcript . | Clinical outcome after CT/clinical status . | Karyotype . |
|---|---|---|---|---|---|
| 1 | F/47 | ICE/NOVIA/FLAG | A | CR/relapse, died | 46,XX(6)/46,XX,inv(16)(p13q22)(6)46,XX,imv(16) (p13q22)(14)/46,XX,t(2;17)(q31;p13)inv(16)(p13q22)(1)* |
| 2 | F/51 | ICE/NOVIA/FLAG/ABMT | A | CR/AW | 46,XX(3)/46,XX,inv(16)(p13q22)(7) |
| 3 | M/34 | ICE/NOVIA/ABMT | A | CR/AW | 46,XY(1)/46,XY,del(7)(q22),inv(16)(p13q22)(13) |
| 4 | M/38 | ICE/NOVIA/BMT | A | CR/AW | 46,XY(2)/46,XY,inv(16)(p13q22)(13) |
| 5 | F/51 | ICE/NOVIA/FLANG/FLANG/BMT | A | CR/breast cancer, died | 46,XX(1)/46,XX,inv(16)(p13q22)(21) |
| 6 | F/58 | ICE/NOVIA/ABMT-PBSC/FLANG/FLANG | A | 2nd CR/AW | 46,XX(2)/46,XX,inv(16)(p13q22)(28) |
| 7 | M/60 | ICE/NOVIA/FLANG/ABMT-PBSC | A | CR/AW | 46,XY(2)/46,XY,inv(16)(p13q22)(19) |
| 8 | M/37 | ICE/NOVIA/BMT | A | CR/AW | 46,XY(3)/46,XY,inv(16)(p13q22)(16) |
| 9 | M/57 | ICE/NOVIA/ABMT | A | CR/AW | 47,XY,inv(16)(p13q22),+22(12)/ 47,XY,t(9;19)(q22;q13),inv(16)(p13q22),+22(8) |
| 10 | M/57 | MEC6/MEC4/ABMT/FLANG/FLANG | A | 2nd CR/AW | 46,XY(1)/46,XY,inv(16)(p13q22)(14) |
| 11 | M/35 | ICE/FLANG/FLANG/ABMT-PBSC | A | 2nd CR/AW | 46,XY(1)/47,XY,inv(16)(p13q22),+9(14) |
| 12 | F/60 | ICE/FLANG/FLANG | D | CR/AW | 46,XX(1)/47,XX,inv(16)(p13q22),+8(30) |
| 13 | M/49 | ICE/FLANG/FLANG/ABMT | A | CR/AW | 46,XY(1)/47,XY,inv(16)(p13q22),+8(28) |
| 14 | M/49 | ICE/FLAN/FLAN/ABMT | A | CR/AW | 46,XY(2)/46,XY,inv(16)(p13q22)(23) |
| 15 | F/27 | FLAI/FLAN/FLAN/ABMT | A | CR/died in 2nd CR | 47,XX,inv(16)(p13q22),+X(25) |
| 16 | F/26 | ICE/FLAN/FLAN/ABMT | E | CR/AW | 46,XX,inv(16)(p13q22)(30) |
| 17 | M/17 | ICE/FLAN/FLAN | A | CR/AW | 46,XY(1)/46,XY,inv(16)(p13q22)(28) |
| 18 | M/16 | ICE/FLAN/FLAN | C | CR/AW | 46,XY,inv(16)(p13q22)(30) |
| 19 | M/63 | Nonablative | A | — | 46,XY(3)/46,XY,inv(16)(p13q22)(23) |
| 20 | M/61 | Nonablative | A | — | 46,XY(2)/46,XY,inv(16)(p13q22)(28) |
| 21 | F/65 | Nonablative | A | — | 46,XX(1)/46,XX,inv(16)(p13q22)(19) |
| Median (range, y) | 49 (16-65) |
| Patient . | Sex/age, y . | Therapy . | Type of transcript . | Clinical outcome after CT/clinical status . | Karyotype . |
|---|---|---|---|---|---|
| 1 | F/47 | ICE/NOVIA/FLAG | A | CR/relapse, died | 46,XX(6)/46,XX,inv(16)(p13q22)(6)46,XX,imv(16) (p13q22)(14)/46,XX,t(2;17)(q31;p13)inv(16)(p13q22)(1)* |
| 2 | F/51 | ICE/NOVIA/FLAG/ABMT | A | CR/AW | 46,XX(3)/46,XX,inv(16)(p13q22)(7) |
| 3 | M/34 | ICE/NOVIA/ABMT | A | CR/AW | 46,XY(1)/46,XY,del(7)(q22),inv(16)(p13q22)(13) |
| 4 | M/38 | ICE/NOVIA/BMT | A | CR/AW | 46,XY(2)/46,XY,inv(16)(p13q22)(13) |
| 5 | F/51 | ICE/NOVIA/FLANG/FLANG/BMT | A | CR/breast cancer, died | 46,XX(1)/46,XX,inv(16)(p13q22)(21) |
| 6 | F/58 | ICE/NOVIA/ABMT-PBSC/FLANG/FLANG | A | 2nd CR/AW | 46,XX(2)/46,XX,inv(16)(p13q22)(28) |
| 7 | M/60 | ICE/NOVIA/FLANG/ABMT-PBSC | A | CR/AW | 46,XY(2)/46,XY,inv(16)(p13q22)(19) |
| 8 | M/37 | ICE/NOVIA/BMT | A | CR/AW | 46,XY(3)/46,XY,inv(16)(p13q22)(16) |
| 9 | M/57 | ICE/NOVIA/ABMT | A | CR/AW | 47,XY,inv(16)(p13q22),+22(12)/ 47,XY,t(9;19)(q22;q13),inv(16)(p13q22),+22(8) |
| 10 | M/57 | MEC6/MEC4/ABMT/FLANG/FLANG | A | 2nd CR/AW | 46,XY(1)/46,XY,inv(16)(p13q22)(14) |
| 11 | M/35 | ICE/FLANG/FLANG/ABMT-PBSC | A | 2nd CR/AW | 46,XY(1)/47,XY,inv(16)(p13q22),+9(14) |
| 12 | F/60 | ICE/FLANG/FLANG | D | CR/AW | 46,XX(1)/47,XX,inv(16)(p13q22),+8(30) |
| 13 | M/49 | ICE/FLANG/FLANG/ABMT | A | CR/AW | 46,XY(1)/47,XY,inv(16)(p13q22),+8(28) |
| 14 | M/49 | ICE/FLAN/FLAN/ABMT | A | CR/AW | 46,XY(2)/46,XY,inv(16)(p13q22)(23) |
| 15 | F/27 | FLAI/FLAN/FLAN/ABMT | A | CR/died in 2nd CR | 47,XX,inv(16)(p13q22),+X(25) |
| 16 | F/26 | ICE/FLAN/FLAN/ABMT | E | CR/AW | 46,XX,inv(16)(p13q22)(30) |
| 17 | M/17 | ICE/FLAN/FLAN | A | CR/AW | 46,XY(1)/46,XY,inv(16)(p13q22)(28) |
| 18 | M/16 | ICE/FLAN/FLAN | C | CR/AW | 46,XY,inv(16)(p13q22)(30) |
| 19 | M/63 | Nonablative | A | — | 46,XY(3)/46,XY,inv(16)(p13q22)(23) |
| 20 | M/61 | Nonablative | A | — | 46,XY(2)/46,XY,inv(16)(p13q22)(28) |
| 21 | F/65 | Nonablative | A | — | 46,XX(1)/46,XX,inv(16)(p13q22)(19) |
| Median (range, y) | 49 (16-65) |
ICE (induction chemotherapy): idarubicin (endovenously infused, 10 mg/m2 per day) for days 1, 3, and 5, cytarabine (100 mg/m2 per day) continuously infused for 10 days, and etoposide (VePesid; 100 mg/m2 per day) for 5 days.29,30 NOVIA (consolidation chemotherapy: cytarabine (500 mg/m2 per day) for 6 days (edovenously infused twice a day for 4 hours) plus mithoxantrone (Novantrone; 12 mg/m2 per day) for 3 days (days 4, 5, 6).32FLAG: 5 days of treatment with a 30-minute infusion of fludarabine (30 mg/m2 per day) followed 4 hours later by a 4-hour infusion of cytarabine (2 g/m2 per day). G-CSF (300 μg/day) was administered subcutaneously before starting fludarabine, continued for 5 days and then given again 1 week after the end of therapy until complete neutrophil recovery.19-21 FLANG: 3 days of fludarabine (30 mg/m2 per day) as above, followed 4 hours later by a 2-hour infusion of cytarabine (1 g/m2 per day) and a 30-minute infusion of mithoxantrone (Novantrone; 10 mg/m2 per day). Twelve hours before fludarabine infusion, G-CSF (300 μg/day) was administered subcutaneously. This was continued for 3 days and then was restarted as in the FLAG regimen.33,34 MEC6 chemotherapy: 6 days of etoposide (VePesid; 100 mg/m2 per day), 30-minute infusion of mithoxantrone (Novantrone; 10 mg/m2 per day), and continuous infusion of cytarabine (100 mg/m2 per day), followed by consolidation chemotherapy (MEC4 protocol). MEC4: 4 days of etoposide (VePesid; 100 mg/m2 per day), 30-minute infusion of mithoxantrone (Novantrone; 10 mg/m2 per day),31 and continuous infusion of cytarabine (100 mg/m2 per day).
Karyotype at relapse. CR indicates complete remission; AW, alive and well.